HHS to invest in domestic production of essential medical supplies
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House announced Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.
Related News Articles
Headline
Baxter has resumed production on all of its 3-liter irrigation and peritoneal dialysis solutions manufacturing lines, the company announced Dec. 5. The company…
Headline
The Food and Drug Administration Dec. 4 announced empty IV bags have been added to its Medical Device Shortages List, and that the shortage is estimated to…
Headline
Baxter Nov. 26 announced new allocation levels for multiple IV product groups and advised customers of a one- to two-week lead time for products to flow…
Headline
Baxter expects to restart a second IV solutions manufacturing line within the next week, the company announced Nov. 7. Along with the first line that resumed…
Headline
Supplies of Mo-99/Tc-99M, which are medical radioisotopes used in procedures to diagnose and detect diseases including heart disease and cancer, are…
Headline
Baxter announced Oct. 31 that it has restarted its North Cove, N.C. facility's highest-throughput IV solutions manufacturing line, which normally accounts for…